Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines

Simple item page
dc.contributor.authorAgache, Ioana
dc.contributor.authorSong, Yang
dc.contributor.authorPosso, Margarita
dc.contributor.authorAlonso-Coello, Pablo
dc.contributor.authorRocha, Claudio
dc.contributor.authorSolà, Ivan
dc.contributor.authorBeltran, Jessica
dc.contributor.authorAkdis, Cezmi A.
dc.contributor.authorAkdis, Mubeccel
dc.contributor.authorBrockow, Knut
dc.contributor.authorChivato, Tomas
dc.contributor.authordel Giacco, Stefano
dc.contributor.authorEiwegger, Thomas
dc.contributor.authorEyerich, Kilian
dc.contributor.authorGiménez-Arnau, Ana
dc.contributor.authorGutermuth, Jan
dc.contributor.authorGuttman-Yassky, Emma
dc.contributor.authorMaurer, Marcus
dc.contributor.authorOgg, Graham
dc.contributor.authorOng, Peck Y.
dc.contributor.authorO'Mahony, Liam
dc.contributor.authorSchwarze, Jürgen
dc.contributor.authorWerfel, Thomas
dc.contributor.authorCanelo-Aybar, Carlos
dc.contributor.authorPalomares, Oscar
dc.contributor.authorJutel, Marek
dc.date.accessioned2021-11-16T15:49:26Z
dc.date.available2021-11-16T15:49:26Z
dc.date.issued2020-07-21
dc.date.updated2021-11-16T12:17:21Z
dc.description.abstractThis systematic review evaluates the efficacy, safety and economic impact of dupilumab compared to standard of care for uncontrolled moderate-to-severe atopic dermatitis (AD). Pubmed, EMBASE and Cochrane Library were searched for RCTs and health economic evaluations. Critical and important AD-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Seven RCTs including 1845 subjects >12 years treated with dupilumab 16 to 52 weeks were evaluated. For adults, there is high certainty that dupilumab decreases SCORAD (MD -30,72; 95% CI -34,65% to -26,79%) and EASI-75 (RR 3.09; 95% CI 2.45 to 3.89), pruritus (RR 2.96; 95% CI 2.37 to 3.70), rescue medication (RR 3.46; 95% CI 2.79 to 4.30), sleep disturbance (MD -7.29; 95% CI -8.23 to -6.35) and anxiety/depression (MD -3.08; 95% CI -4.41 to -1.75) and improves quality of life (MD -4.80; 95% CI -5.55 to -4.06). The efficacy for adolescents is similar. Dupilumab-related adverse events (AEs) slightly increase (low certainty). The evidence for dupilumab-related serious AE is uncertain. The incremental cost-effectiveness ratio ranged from 28 500 pound (low certainty) to 124 541 US$ (moderate certainty). More data on long-term safety are needed both for children and for adults, together with more efficacy data in the paediatric population.Registration: PROSPERO (CRD42020153645).en
dc.description.statusPeer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationAgache, I., Song, Y., Posso, M., Alonso‐Coello, P., Rocha, C., Solà, I., Beltran, J., Akdis, C.A., Akdis, M., Brockow, K. and Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C., Palomares, O. and Jutel, M. (2020) 'Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines', Allergy, 76(1), pp. 45-58. doi: 10.1111/all.14510en
dc.identifier.doi10.1111/all.14510en
dc.identifier.eissn1398-9995
dc.identifier.endpage58en
dc.identifier.issn0105-4538
dc.identifier.issued1en
dc.identifier.journaltitleAllergyen
dc.identifier.startpage45en
dc.identifier.urihttps://hdl.handle.net/10468/12221
dc.identifier.volume76en
dc.language.isoenen
dc.publisherJohn Wiley & Sons, Inc.en
dc.rights© 2020, EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. This is the peer reviewed version of the following item Agache, I., Song, Y., Posso, M., Alonso‐Coello, P., Rocha, C., Solà, I., Beltran, J., Akdis, C.A., Akdis, M., Brockow, K. and Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C., Palomares, O. and Jutel, M. (2020) 'Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines', Allergy, 76(1), pp. 45-58, doi: 10.1111/all.14510, which has been published in final form at: https://doi.org/10.1111/all.14510. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.en
dc.subjectEconomic evaluationsen
dc.subjectAllergic diseasesen
dc.subjectQualityen
dc.subjectValidationen
dc.subjectConsensusen
dc.subjectCosten
dc.subjectInformationen
dc.subjectReliabilityen
dc.subjectEuronheeden
dc.subjectPruritusen
dc.subjectAtopic dermatitisen
dc.subjectEASIen
dc.subjectSCORADen
dc.subjectDupilumaben
dc.subjectCost-effectivenessen
dc.titleEfficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelinesen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
13517_Efficacy.pdf
Size:
19.17 MB
Format:
Adobe Portable Document Format
Description:
Accepted Version
Download
Thumbnail Image
Name:
all14510-sup-0001-supinfo.docx
Size:
31.99 MB
Format:
Microsoft Word XML
Description:
Supporting Information
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medicine - Journal Articles
APC Microbiome Ireland - Journal Articles
Microbiology - Journal Articles